Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 7Sarcoma 5Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 24Thymoma 2Sarcoma 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Adenocarcinoma of Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Celecoxib × Thoracic × Clear all
NCT01313429 2020-03-03

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
19 enrolled
DermatologicSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡